ArticleVaccines2024

Humoral Response and Safety after a Fourth Dose of the SARS-CoV-2 BNT162b2 Vaccine in Cancer Patients Undergoing Active Treatment-Results of a Prospective Observational Study.

Chiara Citterio et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.